Trial Profile
A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 21 Dec 2023
Price :
$35
*
At a glance
- Drugs Alglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Pharmacokinetics
- Acronyms PAPAYA
- Sponsors Sanofi Genzyme
- 01 Dec 2023 Results assessing Pharmacokinetics of Alglucosidase Alfa Manufactured at the 4000-L Scale in Participants with Pompe Disease published in the Clinical Pharmacology in Drug Development
- 11 Dec 2020 Status changed from active, no longer recruiting to completed.
- 26 Oct 2020 Status changed from recruiting to active, no longer recruiting.